Key Takeaways

  • The FDA has granted RMAT designation to Emmecell's investigational corneal endothelial cell therapy EO2002 for corneal edema secondary to corneal endothelial dysfunction
  • EO2002 uses the company's Magnetic Cell Delivery platform to improve therapeutic cell localization and retention, with the goal of restoring corneal endothelial function without donor tissue transplantation
  • RMAT designation provides enhanced opportunities for FDA interaction during development

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Emmecell's investigational therapy EO2002 for the treatment of corneal edema secondary to corneal endothelial dysfunction, the company announced.

The designation applies to EO2002, an allogeneic cultured human corneal endothelial cell therapy that uses Emmecell's proprietary Magnetic Cell Delivery platform. According to the company, the technology is designed to improve the localization and retention of therapeutic cells after administration with the goal of restoring corneal endothelial function without the need for donor corneal tissue transplantation or endothelial keratoplasty.

RMAT designation is intended to facilitate the development and review of regenerative medicine therapies targeting serious or life-threatening conditions when preliminary clinical evidence indicates the potential to address an unmet medical need. The designation provides sponsors with opportunities for increased interaction with the FDA throughout development, including discussions related to clinical trial design, manufacturing, and potential pathways for accelerated approval.

"RMAT designation represents an important regulatory milestone for EO2002 and underscores the potential of our Magnetic Cell Delivery platform to address a meaningful unmet need in corneal endothelial disease," said Ramin Valian, chief executive officer of Emmecell. "We are encouraged by the clinical evidence generated to date and look forward to continued collaboration with the FDA as we advance the EMERALD study. Together with our recent financing and clinical progress, this designation further strengthens our development pathway and reinforces our commitment to delivering a minimally invasive treatment option for patients."